Strategic Partnerships Camino’s collaboration with Sanford Burnham Prebys demonstrates a clear appetite for external R&D partnerships; this positions us to target contract research organizations and academic consortia to accelerate hit discovery, diversify capabilities, and de-risk early programs while keeping the lean team overhead.

Grant Funding Camino recently secured a non-dilutive SBIR grant, signaling readiness to pursue grant-funded programs; there is an opportunity to offer grant-writing support, collaborative project packages, and preclinical services aligned with agency-funded development timelines.

Therapeutic Focus With a focus on first-in-class small molecule therapies for cancer and CNS disorders and leadership with deep target biology expertise, Camino represents an attractive partner for medicinal chemistry, target validation, and early pharmacology services tailored to novel signaling mechanisms.

Digital Needs Operating with a lean tech stack and a boutique footprint, Camino may benefit from scalable digital, data management, and regulatory-compliant tooling (LIMS, secure collaboration platforms, and analytics) to support future discovery and enable partnered programs.

Pharma Licensing As a nimble biotech with credible scientific leadership, Camino is well positioned for out-licensing or co-development deals with larger pharma seeking early-stage oncology or neurology assets and platform access.